Our Story

Since 2002, Lilly Ventures has
focused its investments in
great companies with
compelling life science
innovations that have the
potential to create a
pipeline of life-changing
medicines. We partner actively
with our portfolio company
management teams and
provide intellectual, as
well as financial, resources
to accelerate the path to
success.

Our Team

Our collaborative partnership
leverages the collective
experience, deep expertise,
and networks of our
investment professionals for
the benefit of our portfolio
companies.

Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
01.13.2019

Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

view full story

Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration
01.07.2020

Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration

view full story

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis
01.06.2020

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis

view full story

FORMA Therapeutics Announces Closing Of $100 Million Series D Financing
12.19.2019

FORMA Therapeutics Announces Closing Of $100 Million Series D Financing

view full story

Enrollment complete in Third Phase 3 Clinical Trial for VT-1161 (ultraVIOLET) in Patients with Recurrent Vulvovaginal Candidiasis
12.18.2019

Enrollment complete in Third Phase 3 Clinical Trial for VT-1161 (ultraVIOLET) in Patients with Recurrent Vulvovaginal Candidiasis

view full story

FORMA Therapeutics Announces Positive Preliminary Phase 1/2 IDH1m Inhibitor Olutasidenib Results Demonstrating Rapid Clinical Remissions And Mutation Clearance In Patients With Acute Myeloid Leukemia And Myelodysplastic Syndrome
12.09.2019

FORMA Therapeutics Announces Positive Preliminary Phase 1/2 IDH1m Inhibitor Olutasidenib Results Demonstrating Rapid Clinical Remissions And Mutation Clearance In Patients With Acute Myeloid Leukemia And Myelodysplastic Syndrome

view full story

FORMA Therapeutics Announces Clinical Data For Sickle Cell Disease Candidate FT-4202, Demonstrating Multi-Modal Activity Of PKR Activation Increases Oxygen Affinity And Decreases Sickle Hemoglobin Polymerization, At 61st Annual ASH
12.09.2019

FORMA Therapeutics Announces Clinical Data For Sickle Cell Disease Candidate FT-4202, Demonstrating Multi-Modal Activity Of PKR Activation Increases Oxygen Affinity And Decreases Sickle Hemoglobin Polymerization, At 61st Annual ASH

view full story

Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
12.03.2019

Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia

view full story

FORMA Therapeutics’ Olutasidenib Demonstrates Positive Phase 1b/2 Results, Including Blood-Brain Barrier Penetration And Stable Disease In Patients With IDH1-Mutated Glioma
11.21.2019

FORMA Therapeutics’ Olutasidenib Demonstrates Positive Phase 1b/2 Results, Including Blood-Brain Barrier Penetration And Stable Disease In Patients With IDH1-Mutated Glioma

view full story

Surface Oncology Announces Filing of IND for CD39 Targeted Antibody Candidate, SRF617, at Inaugural R&D Day
11.18.2019

Surface Oncology Announces Filing of IND for CD39 Targeted Antibody Candidate, SRF617, at Inaugural R&D Day

view full story

Enrollment completed early for Global Phase 3 Clinical Trials for VT-1161 (VIOLET) for the Treatment of Recurrent Vulvovaginal Candidiasis
11.12.2019

Enrollment completed early for Global Phase 3 Clinical Trials for VT-1161 (VIOLET) for the Treatment of Recurrent Vulvovaginal Candidiasis

view full story

FORMA’s FASN Inhibitor FT-4101 Significantly Reduced Hepatic De Novo Lipogenesis In Healthy Adult Subjects
11.08.2019

FORMA’s FASN Inhibitor FT-4101 Significantly Reduced Hepatic De Novo Lipogenesis In Healthy Adult Subjects

view full story

Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease
11.06.2019

Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn’s Disease

view full story

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera
10.30.2019

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera

view full story

Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent
10.16.2019

Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent

view full story

Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
10.08.2019

Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors

view full story

Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology
09.28.2019

Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology

view full story

FORMA Therapeutics Announces New Executive Leadership To Execute Next Phase Of Growth For Company
09.24.2019

FORMA Therapeutics Announces New Executive Leadership To Execute Next Phase Of Growth For Company

view full story

Kymera Therapeutics is Named one of FierceBiotech’s “Fierce 15” Companies of 2019
09.23.2019

Kymera Therapeutics is Named one of FierceBiotech’s “Fierce 15” Companies of 2019

view full story

Nimbus Therapeutics Appoints Accomplished Biologist and Research Director Christine Loh, Ph.D., to Lead Biology Team
09.19.2019

Nimbus Therapeutics Appoints Accomplished Biologist and Research Director Christine Loh, Ph.D., to Lead Biology Team

view full story

FORMA Therapeutics Announces Data For IDH1m Inhibitor Olutasidenib In Glioma To Be Presented At The 2019 Society For NeuroOncology Annual Meeting
09.11.2019

FORMA Therapeutics Announces Data For IDH1m Inhibitor Olutasidenib In Glioma To Be Presented At The 2019 Society For NeuroOncology Annual Meeting

view full story

Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium
09.03.2019

Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium

view full story

Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study
08.01.2019

Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study

view full story

Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency
07.24.2019

Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency

view full story

Kymera Therapeutics Announces Leadership Transitions
07.15.2019

Kymera Therapeutics Announces Leadership Transitions

view full story

Nimbus Therapeutics and Celgene Expand Alliance to Immunotherapy in Oncology
07.09.2019

Nimbus Therapeutics and Celgene Expand Alliance to Immunotherapy in Oncology

view full story

Aileron Therapeutics Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer Treated with Chemotherapy
06.27.2019

Aileron Therapeutics Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer Treated with Chemotherapy

view full story

Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach
06.24.2019

Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach

view full story

Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency
06.03.2019

Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency

view full story

Surface Oncology Presents Preclinical Data Further Supporting Anti-Tumor Mechanism of CD73 and CD39 Programs at Brisbane Immunotherapy 2019
05.24.2019

Surface Oncology Presents Preclinical Data Further Supporting Anti-Tumor Mechanism of CD73 and CD39 Programs at Brisbane Immunotherapy 2019

view full story